Section 4 of 6
Clinical evidence
182 evidence topics · 37 sources
Study summaries
EMERGE
Objective
Purpose stated in the ClinicalTrials.gov brief summary
Trial aim stated in the company announcement of initiation
Location and study date
Study dates and status in the ClinicalTrials.gov record
“Study Start (Actual) 2026-06-29” (opens the source at this quote in a new tab)
“Primary Completion (Estimated) 2028-12” (opens the source at this quote in a new tab)
“Study Completion (Estimated) 2031-09” (opens the source at this quote in a new tab)
“First Posted 2026-06-15” (opens the source at this quote in a new tab)
“Last Update Posted 2026-10-30” (opens the source at this quote in a new tab)
“Recruiting” (opens the source at this quote in a new tab)
“No Results Posted” (opens the source at this quote in a new tab)
Number of locations in the ClinicalTrials.gov record
Study locations by country in the ClinicalTrials.gov record
| Country | Locations listed in the record |
|---|---|
| United States | “Pasadena, California, United States, 91106”; “Boca Raton, Florida, United States, 33432”; “Fayetteville, North Carolina, United States, 28304”; “Houston, Texas, United States, 77009” |
| Georgia | “Kutaisi, Georgia”; “Tbilisi, Georgia” |
| Ukraine | “Dnipro, Ukraine”; “Vinnytsia, Ukraine” |
Initiation announced by the company in June 2026
Expected timing of top-line results in the third-quarter 2026 filing
Expected timing of top-line results in the third-quarter 2026 results announcement
Planned update of top-line guidance in the November 2026 corporate deck
Member states and estimated dates in the EU trial record
Status and decision date by member state in the EU trial record
“Denmark Authorised, recruitment pending 28/09/2026” (opens the source at this quote in a new tab)
“France Authorised, recruitment pending 28/09/2026” (opens the source at this quote in a new tab)
“Latvia Authorised, recruitment pending 28/09/2026” (opens the source at this quote in a new tab)
“Portugal Authorised, recruitment pending 29/09/2026” (opens the source at this quote in a new tab)
“Bulgaria Authorised, recruitment pending 29/09/2026” (opens the source at this quote in a new tab)
“Germany Authorised, recruitment pending 30/09/2026” (opens the source at this quote in a new tab)
“Poland Authorised, recruitment pending 01/10/2026” (opens the source at this quote in a new tab)
“Italy Authorised, recruitment pending 01/10/2026” (opens the source at this quote in a new tab)
“Spain Authorised, recruitment pending 02/10/2026” (opens the source at this quote in a new tab)
“Austria Authorised, recruitment pending 05/10/2026” (opens the source at this quote in a new tab)
Study design
Official title in the ClinicalTrials.gov record
Study periods in the ClinicalTrials.gov detailed description
Allocation, model, and masking in the ClinicalTrials.gov record
Design summary in the November 2026 corporate deck
End-of-phase 2 meeting with FDA before the phase 3 trial
Eligibility criteria
Key inclusion criteria in the ClinicalTrials.gov record
“Weight range between 40-130 kg at Screening” (opens the source at this quote in a new tab)
“Acetylcholine receptor antibody (AChR Ab) positive” (opens the source at this quote in a new tab)
“MG-ADL scale score of 6 or more” (opens the source at this quote in a new tab)
“QMG scale score of 10 or more” (opens the source at this quote in a new tab)
“Ages Eligible for Study 18 Years to 80 Years” (opens the source at this quote in a new tab)
Key exclusion criteria in the ClinicalTrials.gov record
Inclusion criteria in the November 2026 corporate deck
Company rationale for the QMG screening criterion
Removal of antinuclear antibody screening after FDA written feedback
Treatment
Arms and interventions in the ClinicalTrials.gov record
Dose and route stated by the company
Rationale for the every-4-weeks regimen from the phase 2 open-label extension
Study outcomes
Rationale for using MG-ADL as the primary endpoint
Primary outcome measure in the ClinicalTrials.gov record
Secondary outcome measures in the ClinicalTrials.gov record
Primary and secondary endpoints stated by the company
MG-ADL scale described in the ClinicalTrials.gov record
Validity, reliability, and use of the MG-ADL as a primary endpoint
“Studies indicated that the MG‐ADL is a reliable and valid measure that has been used as an outcome in clinical trials and observational studies to measure MG symptoms and response to treatment. While most often used as a secondary endpoint in clinical trials, its use as a primary endpoint has increased in recent years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Since trial completion and publication of results for the phase 3 trial of eculizumab, the use of the MG‐ADL as a primary endpoint in trials has become widespread. Of trials beginning in 2018 or later, 46.7% (n = 7) have used the MG‐ADL as a primary outcome compared to 10.0% (n = 2) of trials prior to 2018” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The MG‐ADL is easy to administer, requires no additional training, is quick to complete (<10 min), and can be used in routine clinical” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Minimal clinically important difference: 2-point improvement in the validation study
“Correlation of the delta MG-ADL score and physician impression of change between the visits was strong (r = 0.70, P < 0.0001). A 2-point improvement in the MG-ADL best predicted clinical improvement.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The MG-ADL correlates strongly with newer, validated MG outcome measures. A 2-point improvement in the MG-ADL indicates clinical improvement.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Minimal clinically important difference: sensitivity and specificity of each threshold
“In this study, results from sensitivity and specificity analyses indicated that a 1‐point change in MG‐ADL was highly sensitive (96%) but did not have good specificity (71%), and a 3‐point change had good specificity (90%) but was not very sensitive (62%). A 2‐point change seemed to provide the best balance between sensitivity (77%) and specificity (82%); thus, this analysis revealed that a 2‐point improvement in MG‐ADL score best indicated clinical improvement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of these 13 studies, 53.8% (n = 7) used a 2‐point improvement only, 30.8% (n = 4) used a 3‐point improvement only” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Primary endpoint in the pivotal trial of eculizumab
Primary endpoint in the pivotal trial of ravulizumab
Primary endpoint in the pivotal trial of zilucoplan
Primary endpoints in the pivotal trials of efgartigimod alfa
Primary endpoint in the pivotal trial of rozanolixizumab
Primary endpoint in the pivotal trial of nipocalimab
Company target for the MG-ADL treatment difference
Secondary endpoints: QMG and MGC scales described in the ClinicalTrials.gov record
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment in the ClinicalTrials.gov record
Planned participants per arm in the November 2026 corporate deck
| Arm | Planned participants |
|---|---|
| Claseprubart every 2 weeks | “300mg/2mL S.C. Q2W (N=65)” |
| Claseprubart every 4 weeks | “Claseprubart 300mg/2mL S.C. Q4W (N=65)” |
| Placebo | “Placebo (N=65)” |
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
EMERGE began on 2026-06-29 and has reported no efficacy or safety results; the company expects top-line results in the second half of 2028, and a company presentation lists updated EMERGE top-line guidance by the end of 2027. Enrollment is limited to approximately 195 adults aged 18 to 80 years who are acetylcholine receptor antibody positive, with an MG-ADL score of 6 or more and a QMG score of 10 or more, so participants with anti-MuSK, anti-LRP4, or seronegative generalized myasthenia gravis are not represented. The randomized, placebo-controlled period lasts 17 weeks, and longer-term data will come from an optional 104-week extended treatment period that includes an open-label extension.
MaGic
Objective
Objective of the randomized controlled period
Objective of the top-line results abstract
Objective of the open-label extension analysis
Objective of the minimal symptom expression analysis
Location and study date
Study dates and status in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Recruitment status | “Active, not recruiting” |
| Study start (actual) | “2024-02-23” |
| Primary completion (actual) | “2025-07-28” |
| Study completion (estimated) | “2028-10” |
| First posted | “2024-02-28” |
| Last update posted | “2026-07-27” |
Number of locations and trial identifiers in the ClinicalTrials.gov record
Trial initiation after FDA clearance of the investigational new drug application
Top-line results reported in September 2025
Study design
Study periods in the ClinicalTrials.gov record
Design details in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Study type | “Interventional” |
| Phase | “Phase 2” |
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Quadruple” |
Randomization 1:1:1 to two claseprubart doses or placebo for 13 weeks
Design described at the release of top-line results
Design planned at trial initiation
Open-label extension entry, dosing, and follow-up of participants who declined
Eligibility criteria
Study population summarized in the poster
Inclusion criteria: age, weight, diagnosis, disease class, and MG-ADL score
Exclusion criteria: infection history, viral infections, and thymic disease
Exclusion criteria: prior and concomitant therapy
Exclusion criterion: antinuclear antibody titer
Exclusion of prior C5 complement inhibitor use
Treatment
Arms and interventions in the ClinicalTrials.gov record
| Arm | Day 1 | Week 1 to week 11 |
|---|---|---|
| Placebo comparator: placebo | “Day 1: IV infusion of placebo” | “Week 1 to Week 11: placebo administered SC every 2 weeks” |
| Experimental: claseprubart 300 mg Q2W | “Day 1: IV loading dose” | “Week 1 to Week 11: Claseprubart administered SC every 2 weeks” |
| Experimental: claseprubart 600 mg Q2W | “Day 1: IV loading dose” | “Week 1 to Week 11: Claseprubart administered SC every 2 weeks” |
Intravenous loading dose followed by subcutaneous dosing every 2 weeks
Loading dose by arm and subcutaneous volume
Treatment described at the release of top-line results
Open-label extension dosing for participants switching from placebo
Open-label extension dose unified to 300 mg every 2 weeks
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Registered primary outcome measure: treatment-emergent adverse events and serious adverse events to week 13
Safety and tolerability as the primary endpoint
Primary, key secondary, and key exploratory assessments
Registered secondary outcome measures: long-term safety, serum concentrations, CH50, and antidrug antibodies
Efficacy measure: Myasthenia Gravis Activities of Daily Living scale
Efficacy measure: Quantitative Myasthenia Gravis score
Efficacy measure: minimal symptom expression on MG-ADL and QMG
Efficacy measure: revised 15-item Myasthenia Gravis Quality of Life scale
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment in the ClinicalTrials.gov record
Participants in the pooled claseprubart group of the randomized period
Description of analysis sets
Mixed model for repeated measures for MG-ADL, QMG, and MGC
Logistic regression for minimal symptom expression and general linear model for MG-QoL-15r
One-sided and two-sided significance thresholds
Adjusted logistic regression for MG-ADL and QMG minimal symptom expression
Dual MG-ADL and QMG responder definition and endpoints
“A responder was defined as achieving an improvement in MG‐ADL ≥ 3 and QMG ≥ 4. Endpoints include proportion of dual MG‐ADL and QMG responders at Week 13, time to response, and proportion of responders sustaining response for at least 6 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pooled analysis of the two dose groups in the open-label extension
Results
Participant disposition
Discontinuations in the placebo and 300 mg arms
Entry into the open-label extension and duration of dosing
Baseline characteristics
Demographic and disease characteristics by arm
| Characteristic | Placebo (N=22) | Claseprubart 300 mg Q2W (N=21) | Claseprubart 600 mg Q2W (N=22) |
|---|---|---|---|
| Age, mean (SD), years | “52.2 (16.5)” | “57.1 (13.7)” | “55.3 (12.0)” |
| Male, n (%) | “13 (59%)” | “14 (67%)” | “10 (45%)” |
| Weight, mean (SD), pounds | “195.0 (48.0)” | “192.5 (35.5)” | “179.0 (35.4)” |
| Duration of disease, median (range), years | “7.7 (0.4 – 21.2)” | “3.0 (0.5 – 22.1)” | “7.6 (1.0 – 37.3)” |
| MG-ADL score at baseline, mean (SD) | “8.5 (2.9)” | “8.2 (2.2)” | “8.4 (2.6)” |
| QMG score at baseline, mean (SD) | “14.2 (5.8)” | “12.2 (2.7)” | “12.2 (3.6)” |
| MG Composite score at baseline, mean (SD) | “15.0 (7.8)” | “16.3 (4.5)” | “16.0 (5.3)” |
| MG-QoL-15r score at baseline, mean (SD) | “14.3 (7.0)” | “15.4 (6.6)” | “14.9 (5.9)” |
| MGFA class II at screening, n (%) | “7 (32%)” | “11 (52%)” | “12 (55%)” |
| MGFA class III at screening, n (%) | “12 (55%)” | “10 (48%)” | “9 (41%)” |
| MGFA class IVa at screening, n (%) | “3 (14%)” | “0 (0%)” | “1 (5%)” |
| Prior thymectomy, n (%) | “8 (36%)” | “6 (29%)” | “7 (32%)” |
| Baseline corticosteroid use, n (%) | “19 (86%)” | “17 (81%)” | “20 (91%)” |
| One immunosuppressive therapy at baseline, n (%) | “11 (50%)” | “10 (48%)” | “12 (55%)” |
| More than one immunosuppressive therapy at baseline, n (%) | “11 (50%)” | “11 (52%)” | “10 (45%)” |
| FcRn use in prior 24 months, n (%) | “0 (0%)” | “1 (5%)” | “0 (0%)” |
| Prior complement use, n (%) | “0 (0%)” | “0 (0%)” | “0 (0%)” |
Efficacy results
Week 13 efficacy summary by arm with placebo-adjusted differences
| Measure at week 13 | Placebo (N=22) | Claseprubart 300 mg Q2W (N=21), absolute | Claseprubart 300 mg Q2W, placebo-adjusted (one-sided P) | Claseprubart 600 mg Q2W (N=22), absolute | Claseprubart 600 mg Q2W, placebo-adjusted (one-sided P) |
|---|---|---|---|---|---|
| MG-ADL mean change from baseline | “-2.8” | “-4.6” | “-1.8 (P=0.0113)” | “-5.4” | “-2.6 (P=0.0006)” |
| QMG mean change from baseline | “-2.0” | “-4.4” | “-2.4 (P=0.0144)” | “-4.5” | “-2.5 (P=0.0111)” |
| MSE | “14%” | “37%” | “23% (P=0.0550)” | “27%” | “13% (P=0.1031)” |
| MGC mean change from baseline | “-3.1” | “-8.7” | “-5.6 (P=0.0008)” | “-8.6” | “-5.5 (P=0.0008)” |
MG-ADL change from baseline at week 13 by arm
QMG change from baseline at week 13 by arm
Two-sided P values for MG-ADL and QMG at week 13
| Measure | Claseprubart 300 mg Q2W vs placebo, two-sided P | Claseprubart 600 mg Q2W vs placebo, two-sided P |
|---|---|---|
| MG-ADL | “P=0.0227” | “P=0.0013” |
| QMG | “P=0.0288” | “P=0.0222” |
Week 1 onset of MG-ADL and QMG improvement
Improvement of 5 points or more on MG-ADL and QMG at week 13
Dual MG-ADL and QMG responders at week 13
“Results: 63% of claseprubart patients had dual response improvement in MG‐ADL ≥ 3 and QMG ≥ 4, versus 14% for placebo (OR 29.00; p = 0.0006). Dual responders were seen as early as Week 1. The median time to response was Week 3. All claseprubart patients with dual response at Week 13 had maintained response for at least 6 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
MG-ADL minimal symptom expression at week 13
QMG minimal symptom expression at week 13
MG-ADL minimal symptom expression at week 13 in both dose groups
MGC placebo-adjusted change with 80% confidence intervals
Post hoc subgroup with baseline QMG score of 10 or higher
Open-label extension: sustained response through 65 weeks of treatment
Open-label extension: change from extension baseline to week 52 in the MG-ADL, QMG, and MGC panels
Open-label extension: week 4 response after switching from placebo
Open-label extension: serum concentration after two 600 mg doses
Health-related quality of life and patient-reported outcomes
MG-QoL-15r change from baseline at week 13 by arm with placebo-adjusted differences
| Measure at week 13 | Placebo (N=22) | Claseprubart 300 mg Q2W (N=21), absolute | Claseprubart 300 mg Q2W, placebo-adjusted (one-sided P) | Claseprubart 600 mg Q2W (N=22), absolute | Claseprubart 600 mg Q2W, placebo-adjusted (one-sided P) |
|---|---|---|---|---|---|
| MG-QoL-15r mean change from baseline | “-3.9” | “-6.1” | “-2.2 (P=0.0414)” | “-5.4” | “-1.5 (P=0.1122)” |
MG-QoL-15r change from baseline with standard deviations
Safety results
Safety and tolerability during the 13-week randomized controlled period
| Event, n (%) | Placebo (n=22) | Claseprubart 300 mg Q2W (n=21) | Claseprubart 600 mg Q2W (n=22) |
|---|---|---|---|
| Any treatment-related AEs | “13 (59.1)” | “15 (71.4)” | “21 (95.5)” |
| Clinical AEs | “11 (50.0%)” | “13 (61.9%)” | “15 (68.2%)” |
| Treatment-related serious AEs | “1 (4.5%)” | “0 (0%)” | “0 (0%)” |
| Infections | “10 (45.5%)” | “5 (23.8%)” | “6 (27.3%)” |
| Treatment-related serious infections | “1 (4.5%)” | “0 (0%)” | “0 (0%)” |
| Injection site reactions | “0 (0%)” | “2 (9.5%)” | “2 (9.1%)” |
| Newly positive for ANA | “0 (0%)” | “1 (5.9%)” | “8 (36.4%)” |
| Rashes | “0 (0%)” | “0 (0%)” | “0 (0%)” |
| Arthralgia | “1 (4.5%)” | “1 (4.8%)” | “0 (0%)” |
Table footnotes: clinical adverse events, injection site reactions, and antinuclear antibodies
Severity of treatment-related adverse events, serious adverse events, infections, and autoimmune activation
Most common adverse events in more than 5% of participants in any arm
| Adverse event, n (%) | Placebo (N=22) | Claseprubart 300 mg Q2W (n=21) | Claseprubart 600 mg Q2W (n=22) |
|---|---|---|---|
| Nasopharyngitis | “1 (4.5)” | “3 (14.3%)” | “3 (13.6)” |
| Lipase increased | “0 (0%)” | “3 (14.3%)” | “2 (9.1%)” |
| Upper respiratory tract infection | “3 (13.6%)” | “0 (0%)” | “1 (4.5%)” |
| Sinusitis | “2 (9.1%)” | “0 (0%)” | “0 (0%)” |
| Headache | “2 (9.1%)” | “0 (0%)” | “0 (0%)” |
| Diarrhea | “2 (9.1%)” | “0 (0%)” | “0 (0%)” |
Myasthenia gravis exacerbations in the randomized controlled period
| Event, n (%) | Placebo (N=22) | Claseprubart 300 mg Q2W (n=21) | Claseprubart 600 mg Q2W (n=22) |
|---|---|---|---|
| Myasthenia gravis exacerbations | “2 (9.1%)” | “2 (9.5%)” | “2 (9.1%)” |
Definition and management of myasthenia gravis exacerbations
Infections, autoimmune symptoms, and injection site reactions reported with top-line results
Injection site reaction severity in the top-line abstract
Open-label extension: adverse events through 52 weeks compared with the randomized controlled period
| Adverse event, n (%) | Randomized period: placebo (n=22) | Randomized period: pooled claseprubart (n=43) | Open-label extension: all claseprubart (n=60) |
|---|---|---|---|
| Clinical AEs | “11 (50.0)” | “28 (65.1)” | “45 (75.0)” |
| Related serious AEs | “1 (4.5)” | “0 (0.0)” | “1 (1.7)” |
| Discontinuation due to related AE | “0 (0)” | “0 (0)” | “1 (1.7)” |
| Infections | “10 (45.5)” | “11 (25.6)” | “28 (46.7)” |
| Related serious infections | “1 (4.5)” | “0 (0)” | “1 (1.7)” |
| Injection site reaction | “0 (0)” | “4 (9.3)” | “1 (1.7)” |
| Arthralgia | “1 (4.5)” | “1 (1.7)” | “4 (6.7)” |
| Myasthenia gravis exacerbation | “2 (9.1)” | “4 (9.3)” | “7 (11.7)” |
Open-label extension: table footnotes on the serious infection, discontinuation, and exacerbations
Open-label extension: consistency with the randomized period, meningococcal infections, and one death
Study limitations
Summary
MaGic is a phase 2 trial in which 65 participants with acetylcholine receptor antibody-positive generalized myasthenia gravis were randomized 1:1:1 to claseprubart 300 mg every 2 weeks (21 participants), claseprubart 600 mg every 2 weeks (22 participants), or placebo (22 participants) for 13 weeks. The primary endpoint was safety and tolerability, measured as the incidence of treatment-emergent adverse events and serious adverse events to week 13; MG-ADL, QMG, and MGC were secondary endpoints, and minimal symptom expression and MG-QoL-15r were exploratory. Efficacy comparisons with placebo used one-sided P values, with values below 0.1 considered nominally significant, the MG-ADL result in participants with a baseline QMG score of 10 or higher came from a post hoc analysis of 18 and 16 participants, and the open-label extension pooled both dose groups without a placebo comparison after week 13. The results reported through November 2026 appear in company press releases and presentations and in congress posters and abstracts, and no peer-reviewed full article reporting the trial was identified.
Nominal significance threshold of one-sided P below 0.1
Post hoc analysis of the subgroup with baseline QMG score of 10 or higher
No head-to-head comparison with other therapies
DNTH103-AU-001
Objective
Primary objectives in the Part A and Part B registry record
Secondary objectives in the Part A and Part B registry record
Part C objectives: pharmacokinetics after human normal immunoglobulin G
Objectives stated by the company at study start and at top-line results
Location and study date
Registration, recruitment dates, and status of Parts A and B
Study location, sponsors, and ethics committee
Registration, recruitment dates, and status of Part C
First participant dosed, November 2022
Trial initiation and top-line data dates reported by the company
Study design
Single ascending dose and multiple ascending dose parts
Randomization and blinding of Parts A and B
Part C: open-label, uncontrolled single cohort
First-in-human design described by the company
Eligibility criteria
Key inclusion criteria
Key exclusion criteria
Part C eligibility
Treatment
Planned Part A single-dose cohorts
“SAD IV1, 1 mg/kg” (opens the source at this quote in a new tab)
“SAD IV2, 3 mg/kg” (opens the source at this quote in a new tab)
“SAD IV3, 10 mg/kg” (opens the source at this quote in a new tab)
“SAD IV4, 30 mg/kg” (opens the source at this quote in a new tab)
“SAD IV5, 60 mg/kg” (opens the source at this quote in a new tab)
“SAD SC1, 300 mg” (opens the source at this quote in a new tab)
“SAD SC2, 600 mg” (opens the source at this quote in a new tab)
Planned Part B multiple-dose cohorts
Dose cohorts reported as dosed
Part C: intravenous immunoglobulin before a single dose of DNTH103
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Primary safety endpoints and adverse event grading
Safety as the purpose of a first-in-human study
Secondary pharmacokinetic, pharmacodynamic, and immunogenicity endpoints
“Maximum concentration (Cmax)” (opens the source at this quote in a new tab)
“Terminal elimination half-life (t½)” (opens the source at this quote in a new tab)
“Absolute bioavailability (Fabs)” (opens the source at this quote in a new tab)
“CH50 (complement haemolysis 50%) in serum ex vivo” (opens the source at this quote in a new tab)
“Incidence of anti-drug antibody (ADA) to DNTH103” (opens the source at this quote in a new tab)
Part C: pharmacokinetics as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment and sample size basis in the Part A and Part B registry record
Final accrual in the registry records, last updated June 2025
Participants by part reported in January 2024
Participants reported in the annual report filed March 2025
Description of analysis sets
Safety, pharmacokinetic, pharmacodynamic, and immunogenicity populations
Results
Participant disposition
Participants who completed dosing, as of December 2023
Completion of treatment after injection site reactions
Baseline characteristics
No evidence found.
Efficacy results
Pharmacokinetic results: half-life and dose proportionality
Pharmacodynamic results: classical pathway inhibition and simulated steady state
Dose selection for later trials based on phase 1 data
Part C pharmacokinetics after immunoglobulin G
No evidence found.
Health-related quality of life and patient-reported outcomes
Not applicable.
Safety results
Overall tolerability, serious adverse events, and infections
Adverse events reported across the eight cohorts
Injection site reactions, infusion events, and vomiting
Antinuclear antibody positivity in the 50 mg/kg intravenous cohort
Part C safety
No evidence found.
Study limitations
Summary
DNTH103-AU-001 enrolled healthy adults aged 18 to 65 years and excluded people with a history of autoimmune disease, so its safety, pharmacokinetic, and pharmacodynamic findings come from a population without the diseases claseprubart is being developed to treat, and the company states that the same results may not be seen in patients in later trials. Each dose cohort was planned with 8 participants (6 receiving DNTH103 and 2 receiving placebo); the company reported 52 healthy volunteers in seven cohorts in its top-line announcement and 60 healthy volunteers in eight cohorts who completed dosing as of December 2023, while the registry records a final accrual of 68 for Parts A and B and 9 for the open-label, uncontrolled Part C. The ACTRN12622001265763 record lists recruitment in Christchurch, New Zealand, and neither registry record has uploaded results documents, so the available results come from company press releases, presentations, and annual reports, and no Part C result has been reported. The company states that FDA acceptance of data from trials conducted outside the United States is subject to conditions the FDA imposes.